Emergent BioSolutions (EBS) Gross Profit (2011 - 2026)

Emergent BioSolutions has reported Gross Profit for 16 years, with the latest figure at $137.2 million in Q2 2026.

• On a quarterly basis, Gross Profit rose 85.41% year-over-year to $137.2 million in Q2 2026; TTM through Jun 2026 was $430.3 million, a 5.55% decrease from a year earlier, with the FY2025 full-year figure at $416.7 million, up 15.02% from the prior year.
• Gross Profit was $137.2 million for Q2 2026 at Emergent BioSolutions, up from $84.1 million in the prior quarter.
• The five-year high for Gross Profit was $171.2 million in Q3 2024, with the low at -$41.4 million in Q2 2024.
• Average Gross Profit over 5 years is $101.2 million, with a median of $93.2 million recorded in 2022.
• The largest YoY upside for Gross Profit was 1266.67% in 2024 against a maximum downside of 128.11% in 2024.
• Over 5 years, Gross Profit stood at $162.4 million in 2022, then slumped by 43.66% to $91.5 million in 2023, then declined by 16.17% to $76.7 million in 2024, then decreased by 16.82% to $63.8 million in 2025, then soared by 115.05% to $137.2 million in 2026.
• The last three Gross Profit figures came in at $137.2 million (Q2 2026), $84.1 million (Q1 2026), and $63.8 million (Q4 2025), per Business Quant data.